Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0696 • ACR Convergence 2022
The Mortality Trends Related to SLE in the United States – A 20-year Analysis (2001-to 2020) from the WONDER Database
Ikwinder Preet Kaur¹, Harjot Jagdey², hasan Mirza³, Waqar Mughal⁴ and Pankaj Bansal⁵, ¹Rutgers/Monmouth Medical Center, Long branch, NJ, ²BronxCare Hospital, Bronx, NY, ³Berkshire Medical Center, Pittsfield, MA, ⁴DHQ teaching hospital, Gujrat, Pakistan, ⁵Mayo Clinic, Eau Claire, WI
Background/Purpose: SLE is an autoimmune rheumatic disease that contributes to increased morbidity and mortality due to multi-organ involvement, infections, and accelerated atherosclerosis leading to cardiovascular…
Abstract Number: 0958 • ACR Convergence 2022
Azathioprine Metabolite Levels and Outcomes During Pregnancies in Women with Rheumatic Disease
Stephen Balevic¹, Catherine Sims², Amanda Eudy³ and Megan Clowse², ¹Duke Clinical Research Institute, Durham, NC, ²Duke University, Durham, NC, ³Duke University, Raleigh, NC
Background/Purpose: Despite the wide use of AZA during pregnancy, there are no studies evaluating the impact of pregnancy on AZA metabolites 6-thioguanine nucleotide (6-TGN) and…
Abstract Number: 0979 • ACR Convergence 2022
Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus: A Pooled Post Hoc Analysis of Five Phase 3, Randomized, Placebo-Controlled Clinical Trials
Susan Manzi¹, Jorge Sanchez-Guerrero², Naoto Yokogawa³, Joerg Wenzel⁴, Josephine C. Ocran-Appiah⁵, Munther Khamashta⁶, Julia H N Harris⁷, Bernie Rubin⁸, Norma Lynn Fox⁹, Roger A Levy¹⁰ and Victoria Werth¹¹, ¹Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, ²University of Toronto, Division of Rheumatology, Department of Medicine Mount Sinai Hospital/University Health Network, Toronto, ON, Canada, ³Tokyo Metropolitan Tama Medical Center, Department of Rheumatic Diseases, Tokyo, Japan, ⁴University Hospital of Bonn, Department of Dermatology and Allergy, Bonn, Germany, ⁵GlaxoSmithKline, Clinical Science Immunology, Rockville, MD, ⁶GlaxoSmithKline, Medical Affairs, Dubai, United Arab Emirates, ⁷GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, ⁸GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, ⁹GlaxoSmithKline, Clinical Development *At time of study, Collegeville, PA, ¹⁰GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ¹¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia
Background/Purpose: Mucocutaneous manifestations affect >80% of patients (pts) with SLE and can contribute to their poor quality of life through unwanted attention, self-consciousness, emotional symptoms,…
Abstract Number: 0996 • ACR Convergence 2022
Tapering of Corticosteroids or Immunosuppressive Therapy in Stable SLE: A Comparison of Complete Remission, Clinical Remission and Lupus Low Disease Activity State in Protection Against Flares
Jiacai Cho¹, liang shen², Molla Huq³, Rangi Kandane-Rathnayake⁴, Vera Golder⁴, Worawit Louthrenoo⁵, Yi-Hsin Chen⁶, Laniyati Hamijoyo⁷, Luo Shue Fen⁸, Yeong-Jian Wu⁸, Leonid Zamora⁹, Zhouli Zhang¹⁰, An Yuan¹¹, Sargunan Sockalingam¹², Yasuhiro Katsumata¹³, Masayoshi Harigai¹³, Yanjie Hao³, Zhanguo Li¹⁴, Duminda Basnayake¹⁵, Madelynn Chan¹⁶, Jun Kikuchi¹⁷, Tsutomu Takeuchi¹⁸, Sang-Cheol Bae¹⁹, Fiona Goldblatt²⁰, Shereen Oon²¹, Sean O'Neill²², Kathy Gibson²², Kristine Ng²³, Hui Nee Annie Law²⁴, Nicole Tugnet²⁵, Sunil Kumar²⁶, Cherica Tee²⁷, Michael Tee²⁷, Naoaki Ohkubo²⁸, Yoshiya Tanaka²⁸, Sandra Navarra²⁹, Chak Sing³⁰, Alberta Hoi³¹, Eric Morand³², Mandana Nikpour³³ and Aisha Lateef³⁴, ¹National University Health System (NUHS), Singapore, Singapore, ²National University of Singapore, Singapore, Singapore, ³The University of Melbourne, Melbourne, Australia, ⁴Monash University, Clayton, Australia, ⁵Chiang Mai University, Chiang Mai, Thailand, ⁶Taichung Veterans General Hospital, Taichung, Taiwan, ⁷Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, ⁸Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁹University of Santo Tomas Hospital, Manila, Philippines, ¹⁰Peking University First Hospital, Beijing, China, ¹¹Peking University Health Science Center, Beijing, China, ¹²University of Malaya, Kuala Lumpur, Malaysia, ¹³Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ¹⁴People's Hospital, Peking University Health Science Center, Beijing, China, ¹⁵Teaching Hospital Kandy, Kandy, Sri Lanka, ¹⁶Tan Tock Seng Hospital, Singapore, Singapore, ¹⁷Keio University, Tokyo, Japan, ¹⁸Keio University and Saitama Medical University, Tokyo, Japan, ¹⁹Hanyang University Medical Center, Seoul, Republic of Korea, ²⁰Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, Australia, ²¹St Vincent's Hospital, Fitzroy, Australia, ²²Liverpool Hospital, Sydney, Australia, ²³North Shore Hospital, Auckland, New Zealand, ²⁴Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ²⁵Greenlane Clinical Centre, Auckland, New Zealand, ²⁶Middlemore Hospital, Auckland, New Zealand, ²⁷University of the Philippines, Quezon City, Philippines, ²⁸University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ²⁹University of Santo Tomas, Manila, Philippines, ³⁰The University of Hong Kong, Pok Fu Lam, Hong Kong, ³¹Monash Health, Melbourne, Australia, ³²Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia, ³³The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia, ³⁴National University Hospital, Singapore, Singapore
Background/Purpose: Proposed targets of SLE treatment include lupus low disease activity state (LLDAS), clinical remission and complete remission. Whether treatment can be tapered after achieving…
Abstract Number: 1139 • ACR Convergence 2022
Molecular Pathways Identified from Risk Alleles Identify Mechanistic Differences in Systemic Lupus Erythematosus Patients of East Asian and European Ancestry
Katherine Owen¹, Kristy Bell², Andrew Price³, Prathyusha Bachali⁴, Hannah Ainsworth⁵, Miranda Marion⁶, Timothy Howard⁵, Carl Langefeld⁷, Nan Shen⁸, Jinoos Yazdany⁹, Maria Dall'Era¹⁰, Amrie Grammer¹¹ and Peter Lipsky³, ¹RILITE, Crozet, VA, ²AMPEL BioSolutions LLC, Charlottesville, VA, ³AMPEL BioSolutions, Charlottesville, VA, ⁴AMPEL BioSolutions, Redmond, WA, ⁵Wake Forest School of Medicine, Winston-Salem, NC, ⁶Wake Forest University, Winston-Salem, NC, ⁷Wake Forest School of Medicine, Winston Salem, NC, ⁸Shanghai Jiang Tong University School of Medicine, Shanghai, China, ⁹UCSF, San Francisco, CA, ¹⁰University of California, Division of Rheumatology, San Francisco, CA, ¹¹AMPEL LLC, Charlottesville, VA
Background/Purpose: SLE is a multi-organ autoimmune disorder with a prominent genetic component. Individuals of Asian-Ancestry (AsA) disproportionately experience more severe SLE compared to individuals of…
Abstract Number: 1344 • ACR Convergence 2022
Patient-reported Outcomes in Lupus Low Disease Activity State: Impact of Fatigue
Rodrigo De Moura Rodrigues, Alexandre Moura dos Santos, Daniel Sampaio Cardoso, Emily Figueiredo Neves Yuki, Danieli Castro Oliveira de Andrade, Sandra Gofinet Pasoto, Eduardo Ferreira Borba Neto, Eloisa Silva Dutra de Oliveira Bonfa and Luciana Seguro, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Patient Reported Outcomes (PROs) can be assessed by self-administered questionnaires and can lead to better decision-making by physicians. The aim of this study was…
Abstract Number: 1441 • ACR Convergence 2022
Prevalence of Secondary Connective Tissue Diseases and Autoantibodies Among Racial and Ethnic Groups in Systemic Lupus Erythematosus Patients in the Manhattan Lupus Surveillance Program
Brendan Denvir¹, Philip Carlucci², Jill Buyon³, H Michael Belmont⁴, Kelly Corbitt¹, Sara Sahl⁵, Jane Salmon⁶, Anca Askanase⁷, Joan Bathon⁷, Laura Geraldino-Pardilla⁸, Yousaf Ali⁹, Ellen M. Ginzler¹⁰, Chaim Putterman¹¹, Caroline Gordon¹², Hilary Parton¹³ and Peter Izmirly³, ¹New York University, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵Harbor-University of California Medical Center, Los Angeles, CA, ⁶Hospital for Special Surgery, New York, NY, ⁷Columbia University Medical Center, New York, NY, ⁸Columbia University, New York, NY, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ¹¹Albert Einstein College of Medicine, Bronx, NY, ¹²Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹³New York City Department of Health and Mental Hygiene, New York, NY
Background/Purpose: Epidemiologic data of secondary connective tissue disease and autoantibody profiles among patients with systemic lupus erythematosus (SLE) remains limited for racial/ethnic populations in the…
Abstract Number: 1457 • ACR Convergence 2022
Baseline Characteristics of a Longitudinal, Multinational, Multiethnic Study of Lupus Patients, with or Without Lupus Nephritis
Romina Nieto¹, Rosana Quintana², eduardo Borba³, Lucia Hernandez⁴, Diana Fernandez-Avila⁵, Laura Maurelli⁶, Paul Alba⁷, Florencia Bordon⁸, Fernando Arizpe⁹, Guillermo Berbotta¹⁰, Rosa Serrano-Morales¹¹, Maria Constanza Bertolaccini¹², Eduardo Kerzberg¹³, Maria Angeles Gargiulo¹⁴, Anabella Rodriguez¹⁵, Vitalina Barbosa¹⁶, Andres gasparin¹⁷, Fernando Cavalcanti¹⁸, Laissa Alves Alvino¹⁹, Luciana Parente Costa Seguro²⁰, Lucas Victoria de Oliveira Martins²¹, oscar Niera²², Loreto Massardo²³, Gustavo Aroca Martinez²⁴, Ivana Nieto Aristizabal²⁵, Paul Mendez Patarroyo²⁶, Antonio iglesias Gamarra²⁴, Andres Zuniga Vera²⁷, Olga-Lidia Vera-Lastra²⁸, Mario Perez Cristobal²⁹, Eduardo Martin-Nares³⁰, Luis M Amezcua-Guerra³¹, Yelitza Gonzalez-Bello³², Octavio Gonzalez Enriquez³³, Dionico Galarzo-Delgado³⁴, Carolina Vazquez³⁵, Marcelo barrios³⁶, Magaly Alba Linares³⁷, Cristina Reategui³⁸, Ana Quiroz-Alva³⁹, Teresandris Polanco Mora⁴⁰, Carina Pizzarossa⁴¹, Martin Rebella⁴², Maria Crespo⁴³, Alvaro Danza⁴⁴, Eloisa Silva Dutra de Oliveira Bonfa⁴⁵, Graciela Alarcón⁴⁶, Federico Zazzetti⁴⁷, Ashley Orillion⁴⁸, Guillermo Pons-Estel⁴⁹ and Urbano Sbarigia⁵⁰ ¹GO-CREAR, Rosario, Santa Fe, Argentina, ²Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ⁴Instituto de Investigaciones Teóricas y Aplicadas. Facultad de Ciencias Económicas y Estadistica. Universidad Nacional de Rosario, Rosario, Argentina, ⁵Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Hospital Italiano de Córdoba, Córdoba, Argentina, ⁷Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ⁹Hospital HIGA San Martín, San Martín, Argentina, ¹⁰Sanatorio Británico, Rosario, Argentina, ¹¹Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumáticas del Grupo Oroño, Rosario, Argentina, ¹²Hospital Padilla, San Miguel de Tucuman, Argentina, ¹³Hospital General de Agudos Dr. Ramos Mejia, Buenos Aires, Argentina, ¹⁴Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, ¹⁵CEMIC, Galvan, Argentina, ¹⁶Universidade Federal de Goiás, Goiana, Brazil, ¹⁷Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ¹⁸Universidad Federal de Pernambuco, Recife, Brazil, ¹⁹Hospital Universitario Pedro Ernesto, UERJ, Rio de Janiero, Brazil, ²⁰Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²¹Universidad Federal São Paulo, São Paulo, Brazil, ²²Hospital del Salvador, Providencia, Chile, ²³Universidad San Sebastián, Santiago de Chile, Chile, ²⁴Clínica de la Costa Ltda., Barranquilla, Colombia, ²⁵Fundación Valle del Lili, Calí, Colombia, ²⁶Fundación Santa Fe, Bogotá, Colombia, ²⁷Hospital Luis Vernaza, Guayaquil, Ecuador, ²⁸Centro Médico La Raza, Ciudad de México, Mexico, ²⁹Centro Médico Nacional Siglo XXI, Ciudad de México, Mexico, ³⁰Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³¹Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, ³²Centro de Estudios de investigación Básica y Clínica S.C, Jalisco, Mexico, ³³Hospital Central Dr. Ignacio Morones Prieto, San Luis, Mexico, ³⁴Hospital Universitario "Dr. José Eleuterio Gonzalez", Monterrey, Mexico, ³⁵Hospital de Clínicas I, Montevideo, Uruguay, ³⁶Hospital de Clínicas II, Montevideo, Uruguay, ³⁷Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ³⁸Hospital Nacional Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ³⁹Hospital Cayetano Heredia, San Martín de Porres District, Peru, ⁴⁰Hospital Docente Padre Billini, Santo Domingo, Dominican Republic, ⁴¹Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ⁴²Departamento de Medicina, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, ⁴³Hospital Señor del Milagro, Salta, Argentina, ⁴⁴Grupo de Investigacion de EAIS y Reumatológicas, A Coruña, Spain, ⁴⁵Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴⁶The University of Alabama at Birmingham, Oakland, ⁴⁷Janssen Medical Affairs Global Services, LLC, Buenos Aires, Argentina, ⁴⁸Janssen, Horsham, PA, ⁴⁹CREAR, Rosario, Argentina, ⁵⁰Johnson & Johnson, Beerse, Belgium
Background/Purpose: Clinically evident kidney disease eventually occurs in up to one-half of SLE patients. The aim of this study is to describe sociodemographic, clinical, serological…
Abstract Number: 1477 • ACR Convergence 2022
Prevalence and Risk Factors of Fragility Fractures in Systemic Lupus Erythematosus: A Longitudinal Study over 12 Years
Chi Chiu Mok¹, Kar Li Chan², Ling Yin Ho³ and Chi Hung To⁴, ¹Tuen Mun Hospital, Hong Kong, China, ²Tuen Mun Hospital, Tsing Yi, Hong Kong, China, ³Tuen Mun Hospital, Hong Kong SAR, China, ⁴Hospital Authority, Hong Kong, Hong Kong
Background/Purpose: To study the prevalence and risk factors of fragility fractures in a longitudinal cohort of patients with SLE.Methods: All patients who fulfilled ≥4 1997…
Abstract Number: 1634 • ACR Convergence 2022
Association of Ultra-processed Food Intake with Risk of Systemic Lupus Erythematosus in Women
Sinara Laurini Rossato¹, Chun-Han Lo², Medha Barbhaiya³, Jeffrey Sparks⁴, Neha Khandpur⁵, Susan Malspeis⁶, Kazuki Yoshida⁶, Walter C. Willett⁷ and Karen Costenbader⁶, ¹Universidade Federal de Uberlândia, Uberlândia, Brazil, ²Kirk Kerkorian School of Medicine at UNLV, Las Vegas, ³Hospital for Special Surgery, New York, NY, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Harvard TH Chan School of Public Health, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Harvard TH Chan School of Public Health, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Antioxidants and vitamins present in unprocessed foods may protect against development of systemic lupus erythematosus (SLE) whereas ultra-processed foods (UPFs) remove these nutrients, adding…
Abstract Number: 1713 • ACR Convergence 2022
Bank1 Signaling Shapes the Gut Microbiota Composition by Controlling the Gut Mucosal B-cell Response in Lupus
Georgina Galicia-Rosas, María Botía Sánchez, Daniel Toro-Domínguez, Lorena Albadalejo and Marta Alarcon-Riquelme, Center for Genomics and Oncological Research (GENYO), Granada, Spain
Background/Purpose: Mucosa-associated commensal bacteria have been shown to be involved in the pathogenesis of systemic lupus erythematosus (SLE). However, its exact role remains to be…
Abstract Number: 1934 • ACR Convergence 2022
Transition Readiness Before versus After Adolescents with Rheumatic Disease Transition to Adult Care
Christina Ma¹, Alessana Carmona², Habeba Talaat², Julie Herrington³, Tania Cellucci⁴, Stephanie Garner², Mark Matsos², KAREN BEATTIE² and Michelle Batthish², ¹McMaster University, Canada, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³ACPAC, Hamilton, ON, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: The transition from pediatric to adult rheumatology care is associated with increased disease activity and morbidity for patients with rheumatic disease. Consequently, there has…
Abstract Number: 2064 • ACR Convergence 2022
Trajectories of Disease Activity in a Longitudinal Registry of Pediatric SLE
Siobhan Case¹, Larry Hill², Anne Dennos³, Thomas Phillips⁴, Laura Schanberg⁵, Emily von Scheven⁶, Andrea Knight⁷, Aimee Hersh⁸ and Mary Beth F. Son⁹, ¹Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, ²Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, ³Duke University, Durham, NC, ⁴Duke Clinical Research Institute, Durham, NC, ⁵Duke University Medical Center, Durham, NC, ⁶University of California, San Francisco, San Francisco, CA, ⁷The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁸University of Utah, Salt Lake City, UT, ⁹Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Pediatric systemic lupus erythematosus (pSLE) is associated with significant morbidity and multiorgan dysfunction. Single-center studies have described disease activity and damage trajectories for pSLE,…
Abstract Number: 2082 • ACR Convergence 2022
A Prospective Study on Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol Without Maintenance Therapy
Dario Roccatello¹, Savino Sciascia², Carla Naretto¹, Mirella Alpa¹, Roberta Fenoglio¹, Michela Ferro¹, Giacomo Quattrocchio¹, Elena Rubini¹, Elnaz Rahbani¹, Vittorio Modena¹ and Daniela Rossi¹, ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy
Background/Purpose: We aimed to investigate the safety and efficacy of an intensified B-cell depletion induction therapy (IBCDT) without immunosuppressive maintenance regimen compared with standard of…
Abstract Number: 2102 • ACR Convergence 2022
Does Remission According Definition of Remission in SLE (DORIS) 2021 Match the Treating Rheumatologist Judgment? Analysis at Recruitment of a Prospective Study of 500 SLE Patients from a Spanish Multicenter Cohort
Irene Altabas Gonzalez¹, Coral Mouriño Rodriguez¹, Iñigo Rúa-Figueroa², Francisco Rubiño³, Iñigo Hernandez Rodriguez¹, Raul Menor Almagro⁴, Esther Uriarte Isacelaya⁵, Eva Tomero Muriel⁶, Tarek Carlos Salman-Monte⁷, Irene Carrion Barbera⁸, maria Galindo⁹, Esther Rodriguez Almaraz⁹, Norman Jimenez¹⁰, Luis Ines Sousa¹¹ and Jose M Pego-Reigosa¹², ¹Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ²Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, ³Hospital Universitario de Jerez de la Frontera, Jerez de la frontera, Spain, ⁴Hospital Jerez de la Frontera, Cádiz, Spain, ⁵Hospital Universitario Donostia, Donostia, Spain, ⁶Hospital Universitario La Princesa, Madrid, Spain, ⁷Hospital del Mar/Parc de Salut Mar-IMIM/UEC-AIS, Barcelona, Spain, ⁸Hospital del Mar, Rheumatology, Barcelona, Spain, ⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁰IRIDIS Group, Vigo, Spain, ¹¹Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal, ¹²Hospital Meixoeiro, Vigo, Spain
Background/Purpose: An accurate target in Systemic Lupus Erythematosus (SLE) Treat to Target strategies has been challenging over the past years. Recently, a new definition of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].